Incyte's vision is to become a leading drug discovery and development company by building a proprietary product pipeline of novel small molecule drugs. We have an experienced team with prior success in bringing important new drugs to market. We believe we have the resources, experience and drive to improve the lives of patients and build sustainable value for our shareholders.
WILMINGTON, Del., May 01, 2012 (BUSINESS WIRE) --Incyte Corporation (Nasdaq: INCY) announced today it will present at the
Bank of America Merrill Lynch 2012 Health Care Conference on Tuesday,
May 15, 2012 at 11:20 a.m. (PT) / 2:20 p.m. (ET) in Las Vegas.
The presentation will be webcast live and can be accessed at www.incyte.com
under Investor Relations, Events and Webcasts. A replay of the
presentation will be available for 90 days. Investors interested in
...
$19.3 million in first-quarter net product revenue from JakafiTM
(ruxolitinib); $25.1 million of Jakafi shipped to
specialty pharmacies during the quarter
Phase III studies of Jakafi published in The New England Journal
of Medicine demonstrate significant clinical benefit for patients with
myelofibrosis
Conference Call Scheduled Today at 8:30 a.m. ET
WILMINGTON, Del., Apr 26, ...
WILMINGTON, Del., Apr 20, 2012 (BUSINESS WIRE) --Incyte Corporation (Nasdaq: INCY) announced today a European
Union (EU) regulatory milestone from Novartis. The milestone includes a
$40 million payment earned based on the recommendation by the Committee
for Medicinal Products for Human Use (CHMP) of the European
Medicines Agency (EMA) for approval of ruxolitinib for the treatment of
disease-related splenomegaly or symptoms in adult patients with primary
...
Notice To Readers: Incyte's press releases, presentations and printed remarks are included on this Web site for historical purposes only. The information contained in these documents and webcasts should be considered accurate only as of the date of the relevant document or presentation. This information may change over time; therefore, visitors to this Web site should not assume that the information contained in these documents or presentations remains accurate at a later time. We do not have any current intention, and expressly disclaim any obligation, to supplement, update or revise any of the information in these documents or presentations.
Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.
